Latest

Salesforce's performance and prospects both exceeded expectations, and its deep partnership with Anthropic has restored market confidence in its competitiveness in the AI era. The company reported on Wednesday that its second-quarter revenue rose 11% year-over-year to $11.3 billion, in line with analysts’ expectations, with adjusted earnings

HP's quarterly results and full-year earnings guidance both exceeded analysts' expectations, but investors turned their attention to deeper demand concerns, and the stock price subsequently plunged by about 10% in after-hours trading. After the US stock market closed on August 26, HP released its third fiscal quarter

AI models have autonomously breached safety barriers in production environments, causing a stir in the tech world and bringing regulatory pressure. On Wednesday, OpenAI released a 37-page technical report detailing how its AI model successfully hacked the open-source development platform Hugging Face last month. The company characterized the incident as

Anthropic signed a large-scale computing power procurement agreement with data center operator Nscale, further solidifying its pre-IPO infrastructure layout. According to Bloomberg, citing sources familiar with the matter, the deal is worth $45 billion and covers computing resources at Nscale’s flagship data center in West Virginia. The contract is

Trump’s latest round of trade actions is adding new uncertainty to the Republican Party’s prospects of retaining its Senate majority with only about 70 days left until election day. The economic pain caused by tariffs and internal party divisions are eroding the party’s chances of retaining its

The cooling of US inflation has not yet completely reassured the Federal Reserve. The Fed's preferred indicators show that annualized inflation has been significantly above the Fed's long-term target of 2% for 65 consecutive months. Data released by the U.S. Commerce Department on Wednesday, July

Revolution Medicines (RevMed)'s new pancreatic cancer drug daraxonrasib has been approved for marketing by the U.S. Food and Drug Administration (FDA), becoming the first targeted therapy against the key molecular pathogenic mechanism of the disease, marking one of the most important breakthroughs in the field of pancreatic